A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

NCT00118638 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

705

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Non-Myeloid Malignancies

Interventions

DRUG: Darbepoetin alfa - 2.25 mcg/kg
DRUG: Darbepoetin alfa - 500mcg

Sponsor

Amgen